Effects of IL-15 treatment on sipuleucel-T mediated prostate tumor immunity
Sipuleucel-T is the only FDA-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). IL-15 treatment can enhance the functional anti-tumor efficacy of sip-T, providing rationale for combining IL-15 or IL-15 agonists with sip-T to treat mCRPC patients.